Launceston Hospital
Welcome,         Profile    Billing    Logout  
 1 Trial 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Boden, Ianthe
STTARRS, NCT06631872: Implementing Surgery School Prehabilitation Using Telehealth

Recruiting
N/A
545
RoW
Tele-prehabilitation education session: Surgery School, Individualised Inspiratory Muscle Training and Walking Program, Usual Care
University of Melbourne, Peter MacCallum Cancer Centre, Australia
Lung Cancer, Colorectal Cancer, Oesophageal Cancer, Pancreas Cancer, Gastric Cancer
01/27
01/28
Anagnostou, Nicholas
SNAP, NCT05137119: Staphylococcus Aureus Network Adaptive Platform Trial

Recruiting
4
8000
Europe, Canada, RoW
Cefazolin, Penicillin, Benzylpenicillin, Penicillin G, Clindamycin, Lincomycin, Vancomycin, Daptomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
University of Melbourne, Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, Houston Medical Research Institute
Staphylococcus Aureus Bacteremia
12/28
12/28
Brajković, Ana Vujaklija
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
Duška, František
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
NCT04429919 / 2019-003502-28: AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain

Completed
2
99
Europe, RoW
AP-325, Placebo
Algiax Pharmaceuticals GmbH, FGK Clinical Research GmbH
Peripheral Post-surgical Neuropathic Pain
10/24
10/24
NCT05947955: Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

Recruiting
2
600
Europe, Canada, US
Rhu-pGSN, recombinant human gelsolin, normal saline, 0.9% sterile saline
BioAegis Therapeutics Inc., Biomedical Advanced Research and Development Authority
Acute Respiratory Distress Syndrome, Infections
10/26
03/27
FEBATRICE, NCT05430269: Faecal Bacteriotherapy for Postantibiotic Diarrhoea in Critically Ill Patients

Recruiting
N/A
36
RoW
Faecal bacteriotherapy (FBT), standard-of-care protocolised treatment of postantibiotic diarhea
Charles University, Czech Republic, Faculty Hospital Kralovske Vinohrady, Donatio Intensivistam Endowment Fund
Diarrhea Caused by Drug, Clostridium Difficile Infections
12/24
07/25
Boyd, Mark
SNAP, NCT05137119: Staphylococcus Aureus Network Adaptive Platform Trial

Recruiting
4
8000
Europe, Canada, RoW
Cefazolin, Penicillin, Benzylpenicillin, Penicillin G, Clindamycin, Lincomycin, Vancomycin, Daptomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
University of Melbourne, Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, Houston Medical Research Institute
Staphylococcus Aureus Bacteremia
12/28
12/28
ASCOT, NCT04483960: Australasian COVID-19 Trial () ADAptive Platform Trial

Active, not recruiting
3
2200
RoW
(Arm Closed) Nafamostat Mesilate, Nafabelltan, (Arm Closed) Enoxaparin, (Arm Closed) Dalteparin, (Arm Closed) Tinzaparin, (Arm Never Opened) Hyperimmune globulin, Nirmatrelvir-Ritonavir, Paxlovid, Remdesivir, Veklury
University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Australasian Society for Infectious Diseases, Hunter Medical Research Institute, Aotearoa Clinical Trials, Australian and New Zealand Intensive Care Research Centre
SARS-CoV-2 Infection (COVID-19)
07/25
12/25
Trad, Ali
SNAP, NCT05137119: Staphylococcus Aureus Network Adaptive Platform Trial

Recruiting
4
8000
Europe, Canada, RoW
Cefazolin, Penicillin, Benzylpenicillin, Penicillin G, Clindamycin, Lincomycin, Vancomycin, Daptomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
University of Melbourne, Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, Houston Medical Research Institute
Staphylococcus Aureus Bacteremia
12/28
12/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Boden, Ianthe
STTARRS, NCT06631872: Implementing Surgery School Prehabilitation Using Telehealth

Recruiting
N/A
545
RoW
Tele-prehabilitation education session: Surgery School, Individualised Inspiratory Muscle Training and Walking Program, Usual Care
University of Melbourne, Peter MacCallum Cancer Centre, Australia
Lung Cancer, Colorectal Cancer, Oesophageal Cancer, Pancreas Cancer, Gastric Cancer
01/27
01/28
Anagnostou, Nicholas
SNAP, NCT05137119: Staphylococcus Aureus Network Adaptive Platform Trial

Recruiting
4
8000
Europe, Canada, RoW
Cefazolin, Penicillin, Benzylpenicillin, Penicillin G, Clindamycin, Lincomycin, Vancomycin, Daptomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
University of Melbourne, Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, Houston Medical Research Institute
Staphylococcus Aureus Bacteremia
12/28
12/28
Brajković, Ana Vujaklija
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
Duška, František
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
NCT04429919 / 2019-003502-28: AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain

Completed
2
99
Europe, RoW
AP-325, Placebo
Algiax Pharmaceuticals GmbH, FGK Clinical Research GmbH
Peripheral Post-surgical Neuropathic Pain
10/24
10/24
NCT05947955: Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

Recruiting
2
600
Europe, Canada, US
Rhu-pGSN, recombinant human gelsolin, normal saline, 0.9% sterile saline
BioAegis Therapeutics Inc., Biomedical Advanced Research and Development Authority
Acute Respiratory Distress Syndrome, Infections
10/26
03/27
FEBATRICE, NCT05430269: Faecal Bacteriotherapy for Postantibiotic Diarrhoea in Critically Ill Patients

Recruiting
N/A
36
RoW
Faecal bacteriotherapy (FBT), standard-of-care protocolised treatment of postantibiotic diarhea
Charles University, Czech Republic, Faculty Hospital Kralovske Vinohrady, Donatio Intensivistam Endowment Fund
Diarrhea Caused by Drug, Clostridium Difficile Infections
12/24
07/25
Boyd, Mark
SNAP, NCT05137119: Staphylococcus Aureus Network Adaptive Platform Trial

Recruiting
4
8000
Europe, Canada, RoW
Cefazolin, Penicillin, Benzylpenicillin, Penicillin G, Clindamycin, Lincomycin, Vancomycin, Daptomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
University of Melbourne, Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, Houston Medical Research Institute
Staphylococcus Aureus Bacteremia
12/28
12/28
ASCOT, NCT04483960: Australasian COVID-19 Trial () ADAptive Platform Trial

Active, not recruiting
3
2200
RoW
(Arm Closed) Nafamostat Mesilate, Nafabelltan, (Arm Closed) Enoxaparin, (Arm Closed) Dalteparin, (Arm Closed) Tinzaparin, (Arm Never Opened) Hyperimmune globulin, Nirmatrelvir-Ritonavir, Paxlovid, Remdesivir, Veklury
University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Australasian Society for Infectious Diseases, Hunter Medical Research Institute, Aotearoa Clinical Trials, Australian and New Zealand Intensive Care Research Centre
SARS-CoV-2 Infection (COVID-19)
07/25
12/25
Trad, Ali
SNAP, NCT05137119: Staphylococcus Aureus Network Adaptive Platform Trial

Recruiting
4
8000
Europe, Canada, RoW
Cefazolin, Penicillin, Benzylpenicillin, Penicillin G, Clindamycin, Lincomycin, Vancomycin, Daptomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
University of Melbourne, Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, Houston Medical Research Institute
Staphylococcus Aureus Bacteremia
12/28
12/28

Download Options